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ABSTRACT 
Successful development of an effective HIV vaccine hasn’t occurred yet partly as a consequence of the 
antigenic variation deployed by HIV-1 to escape the immune system. Our laboratory is dedicated to 
develop a single peptide synthesis approach to create multivalent peptides representing hypervariable 
epitopes of the gp120 envelope glycoprotein of HIV-1. Our previous study showed that our HIV HECs 
are potent immunogens that activate both humoral and cellular arms of the acquired immune response 
and that these responses are broadly reactive, recognizing epitopes from divergent strains of HIV-1. To 
detect the long term duration of memory response induced by HIV HECs, two rhesus macaques were 
immunized at weeks 0 and 8 and euthanized two weeks after a third immunization at week 393 (more 
than 8 years later). Antibody response to individual components of HIV HEC immunogens and HIV 
HEC-induced cross-reactive antibody response were determined by an Enzyme-Linked Immunosorbent 
Assay (ELISA). The antibody titer to individual HIV HEC components and a mixture of the five peptides 
was greater than 1:5000 dilution. Antibodies from HIV HEC-immunized macaques recognized HIV HEC 
analogs representing the monovalent epitopes of five variable regions of gp120 from subtype B HIV-1 
MN, HIV-1 RF and HIV-1 SF2 isolates with an antibody titer greater than 1: 500 dilution. Moreover, 
lymphocytes from lymph nodes of HIV HEC-immunized macaques showed T cell proliferative responses 
specific to HIV HEC individual components and to the five HIV HEC peptides combined. Our results 
clearly show that in these two macaques, HIV HECs induced strong, long-lasting anamnestic immune 
responses 8 years after immunization. 
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1. INTRODUCTION 
  For  over  two  decades,  numerous  research  groups 
have tried to develop HIV vaccines (Gallo, 2005; Levy, 
2006). However, no currently available vaccines confer a 
protective  immune  response  against  HIV  infection  or 
delay  AIDS  progression  of  infected  patients  (Ndung’u 
and Weiss, 2012; Saunders et al., 2012). All candidate 
vaccines that  have undergone clinical trials in  humans 
have  resulted  in  lack  of  significant  protection  against 
HIV  infection.  Many  HIV  vaccine  trials  designed  to 
elicit a protective immune response against the envelope 
glycoprotein  gp120  have  been  hampered  because  of 
conformational  masking  of  receptor-binding  sites 
(Kwong  et  al.,  2002),  epitope  occlusion  and 
posttranslational  modification  by  glycosylation 
(Overbaugh and Rudensey, 1992; Wyatt et al., 1998) and 
the  existence  of  immunosuppressor  determinants Rebecca Rivera et al. / American Journal of Immunology 9 (1): 30-35, 2013 
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(Shan  et  al.,  2007).  In  spite  of  these  obstacles, 
development of an effective  HIV vaccine  may  still be 
possible. However, to achieve this goal more knowledge 
of  the  in  vivo  immune  response  at  the  initial  site  of 
infection and the systemic immune responses that control 
HIV replication and disease progression is needed. 
  One  of  the  major  problems  associated  with  the 
development  of  retroviral  vaccines  is  to  overcome  the 
antigenic  variability  of  multiple  epitopes  attributed  to 
error-prone  reverse  transcriptase  and  RNA  polymerase. 
Our  laboratory  has  developed  an  approach  to  prepare 
peptides in a single synthesis that represent the cumulative 
epitope  variability  observed  in  vivo  in  HIV-1  infected 
subjects. HIV Hypervariable Epitope Constructs (HECs) 
are  synthetic  peptide  mixtures  that  contain  multiple 
variants of a given epitope, based on five variable regions 
of the envelope glycoprotein of HIV-1 (gp120).  
  Previously,  we  examined  the  immunogenicity  of 
HIV  HECs  in  animal  studies,  showing  that  the  HIV 
HECs are highly immunogenic, eliciting both  humoral 
and cellular immune responses. However, because of the 
high cost of  nonhuman primate  maintenance,  we  were 
not  able  to  determine  the  long-term  duration  of  the 
immune response elicited by the HIV HECs. In the present 
study, anamnestic antibody and lymphocyte proliferative 
responses assessed eight years after HIV HEC vaccination 
of non-human primates are briefly reported.  
2. MATERIAL AND METHODS 
2.1. HIV HEC Design and Construction 
  The method for synthesizing and designing the HEC 
peptides  based  on  antigenic  variable  regions  of  viral 
proteins  has  been  described  (Anderson  et  al.,  1994; 
2005; Carlos et al., 2000; Reddy et al., 2004; Azizi et al., 
2008). Briefly, amino acid sequence data corresponding 
to  five  hypervariable  immunogenic  regions  of  HIV-1 
gp120  were  obtained  from  Los  Alamos  Human 
Retroviruses and AIDS database. The protein sequences 
from all available isolates were aligned and the possible 
amino  acids  for  each  position  along  the  variable 
epitopes were determined. HIV HECs were synthesized 
by 9-fluorenylmethyloxycarbonyl (Fmoc) chemistry, a 
solid-phase  peptide  synthesis  method,  utilizing  high 
capacity  (0.7mmol/g)  Knorr  resin  (Advanced 
Chemtech). 
2.2. Immunization  of  Rhesus  Macaques  with 
HIV HECs 
  Animals in this study were housed at the California 
National Primate Research Center (Davis, CA) according 
to the regulations of the Association for Assessment and 
Accreditation  of  Laboratory  Animal  Care  International 
standards  and  the  institutional  Animal  Care  and  Use 
Committee  of  the  University  of  California,  Davis.  Two 
adult male rhesus macaques (mac 25598 and mac 25705), 
free  of  Simian  Immunodeficiency  Virus  (SIV),  Simian 
Retrovirus  (SRV)  and  Simian  T-cell  Leukemia  Virus 
(STLV), were immunized intramuscularly (i.m.) with 500 
µg of an equimolar  mixture  of five HIV HEC peptides 
resuspended  in  an  equal  volume  of  Phosphate-Buffered 
Saline (PBS) and Montanide ISA51 adjuvant (Seppic Inc). 
Rhesus macaques were immunized two times at weeks 0 
and  8  and  euthanized  two  weeks  after  a  third 
immunization at week 393 (more than 8 years later). 
2.3. Detection of Antibody Response by ELISA 
  Antibody response to individual components of HIV 
HEC immunogens and HIV HEC-induced cross-reactive 
antibody  response  were  determined  by  an  Enzyme-
Linked Immunosorbent Assay (ELISA). The method of 
performing  ELISA  to  detect  HEC-specific  antibody 
responses  has  been  described  (Carlos  et  al.,  2000; 
Anderson et al., 2005; Kang et al., 2010). Plasma obtained 
prior to immunization was used as negative control.  
2.4. Lymphocyte Proliferative Response 
  Lymph  nodes  were  obtained  on  the  day  of 
euthanization and lymphocytes were isolated by Ficoll-
Paque density gradient centrifugation. 1´10
5 cells per 
well  in  96  well  round-bottom  plates  were  stimulated 
with each individual HIV HEC or with a combination 
of  all  five  HIV  HECs  in  a  final  concentration  of  10 
µg/mL  in  RPMI  1640  medium  containing  10%  Fetal 
Bovine  Serum  (FBS),  L-glutamine  and  antibiotics. 
Following 6 days of culture, 1 µCi of [
3H] thymidine 
was added to each well and cultured for 16-18 h prior 
to  harvest.  [
3H]  thymidine  incorporation  was 
determined  by  measuring  radioactivity  in  an  LKB 
Wallac  liquid  scintillation  counter.  The  results  were 
expressed as Count Per Minutes (CPM). 
2.5. Statistical Analysis 
  The significance of differences between groups
 was 
determined  using  a  paired  Student  t  test  (with  a 
confidence
  level  of  95%)  with  Graph  Pad  Prism 
software,  version  5.01.  Two-tailed  P  values  of  <0.05 
were considered statistically significant. 
3. RESULTS AND DISSCUSSION 
  Our  laboratory  has  developed  a  novel  method  to 
prepare  synthetic  peptide  immunogens  based  on 
antigenic epitopes of variable regions of viral proteins. Rebecca Rivera et al. / American Journal of Immunology 9 (1): 30-35, 2013 
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Fig. 1. HIV HEC-specific antibody response 
 
Sequences  of  HIV  HECs  representing  the  five 
variable  regions  of  gp120  envelope  glycoprotein  of 
HIV-1 are shown in Table 1. Sequences of analogs, 
single  sequence  peptides  representing  the  variable 
regions  of  the  gp120  envelope  glycoprotein  of 
subtype  B  HIV-1  MN,  HIV-1  RF  and  HIV-1  SF2 
isolates are previously described (Carlos et al., 2000).
  In  a  previous  study,  we  evaluated  the 
immunogenicity  of  HIV  HECs  in  rhesus  macaques. 
Two  male  rhesus  macaques  (mac  25598  and  mac 
25705)  were  immunized  intramuscularly  with  HIV 
HECs two times in a two-month interval (week 0 and 
8)  and  both  of  them  developed  strong,  broadly 
reactive  binding  antibodies  and  T  cell  proliferative 
responses  specific  to  the  HIV  gp120  sequences 
represented (Carlos et al., 2000).  
  To  further  understand  the  duration  of  memory 
response  elicited  by  the  HIV  HECs,  these  two 
macaques received a boosting immunization with the 
same amount of HIV HEC  peptide mixture 8  years 
(week  393)  after  the  second  immunization  and  the 
HIV HEC-specific memory response was determined. Rebecca Rivera et al. / American Journal of Immunology 9 (1): 30-35, 2013 
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Table 1. HIV HECs based on the V1-V5 variable regions of gp120 envelope glycoprotein of HIV-1 
Construct and region  HIV HEC Sequence  HLA alleles  Variants 
HEC 1  CTDLKNDTNTTNSTSGRMMMEK  DQA1*0501; 
V1 (aa 130-151)  --- N---- A-------T-N--E-------  DRB1*0301,*0401,*1302,*1501;  32 
    DRB3*0202 
HEC 2  FYKLDIVPIDNTTTSYRRLISC  DPA1*0102,*0201;   
V2 (aa 161-181)  --- -B----------- DSN---------  DQA1*0501;  16 
    DRB1*0101,*0301,*1104,*1301,*1302; 
    DRB3*0202 
HEC 3  NNNTRKSIRIGPGRAFYTTGDIGNIR  DPA1*0102;   
V3 (aa 305-331)  ----------- R-H------ Q--------- E--D---  DQA1*0501; DRB1*0101,*0301,*1501;   32 
HEC 4    DPA1*0102; 
V4 (aa 390-413)  FNSTWFNSTWSTEGSNNTEGSDT  DQA1*0501; DRB1*0402,*0901,*1301;  4 
  ------- S------------ W------------  DRB3*0202   
HEC 5  LTRDGGNNNNESEIFRPGGGD  DQA1*0501; 
V5 (aa 454-475)  -------------- T-T--------  DRB1*0101,*0301,*1302,*1501;  4 
    DRB3*0202   
Positions in which two amino acids are added at a coupling step are highlighted in bold.  Dashes indicate identical amino acid sequence 
in which a single amino is added.  Each HEC contains 4, 16 or 32 variants as indicated.  The locations of the V1-V5 epitopes are 
indicated for a reference strain of virus (HIV-1 MN).  Representative sequences from each HEC were screened for the presence of 
epitopes predicted to bind to any HLA class II epitopes with defined−binding motifs.  Those HLA alleles predicted to bind to an 
epitope contained within the HEC are indicated.  Predictions were made with HLA Ligand and Motif Database funded by NIH. 
 
Plasma  was  obtained  from  HIV  HEC-immunized 
macaques  8  days  after  the  boost  immunization  and 
plasma obtained prior to boosting was used as negative 
control to determine the basal level of antibody response. 
HIV HEC-specific antibody response was determined by 
ELISA.  Antibody  response  was  considered  positive 
when the OD value from plasma of boosted macaques 
was at least twice as that of pre-immunization. The end-
point antibody titer was defined by the highest dilution in 
which antibody response  was considered positive. The 
antibody titer to individual HIV HEC components and a 
mixture  of  the  five  peptides  was  greater  than  1:5000 
dilution  (Fig.  1A).  These  results  suggest  that  both 
macaques still have HIV HEC-specific memory and or 
plasma  B  cells  capable  of  producing  antibodies  that 
recognize each HIV HEC peptide with strong affinity 8 
years after immunization.  
  Two  weeks  after  a  booster  immunization, 
macaques  were euthanized and the cross-reactivity of 
HIV  HEC-induced  antibody  response  and  HIV  HEC-
specific  lymphoproliferative  response  were  assessed. 
Antibodies from HIV HEC-immunized macaques still 
recognized  HIV  HEC  analogs  representing  the 
monovalent epitopes of five variable regions of gp120 
from subtype B HIV-1 MN, HIV-1 RF and HIV-1 SF2 
isolates  with  an  antibody  titer  greater  than  1:500 
dilution (Fig. 1B). These results suggest that a broadly 
reactive,  memory  antibody  response  can  be  detected 
several  years  after  immunization  with  HIV  HECs. 
Moreover,  lymphocytes  from  lymph  nodes  of  HIV 
HEC-immunized macaques showed T cell proliferative 
responses specific to HIV HEC individual components 
and to the five HIV HEC peptides combined (Fig. 1C). 
This result also suggest that the memory T cell response 
induced by the HIV HECs were well preserved even 8 
years after the last immunization.  
 
4. CONCLUSION 
  Most HIV vaccine studies have mainly focused on 
induction of either B cell or CD8 T cell responses (Virgin 
and Walker, 2010). Both an antibody response and killing 
of HIV-infected cells by  CD8 T cells  would need help 
from CD4 T cells to limit HIV infection or reduce HIV 
replication.  A  successful  preventive  or  therapeutic  HIV 
vaccine  should  be  able  to  simultaneously  elicit  CD4  T 
helper cells, CD8 cytotoxic T cells and a broadly, high 
affinity neutralizing antibody response.  
  In our previous studies, we demonstrated that mice, 
rabbits  and  rhesus  macaques  immunized  with  HIV-1 
HECs  developed  strong  antibody  responses  specific  to 
the immunogens and broadly neutralizing antibodies that 
inhibit  viral  infection  of  three  different  HIV-1  strains 
(Carlos et al., 2000). Our laboratory also reported that 
lymphocyte  proliferative  responses  in  HIV  HEC-
immunized  animals  were  specific  to  the  HIV-1  HEC 
immunogens and were cross-reactive to their analogs as 
well as subtype-specific peptides (Carlos et al., 2000). In 
one of our previous studies, rhesus macaques immunized Rebecca Rivera et al. / American Journal of Immunology 9 (1): 30-35, 2013 
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with  SIV  HECs  developed  strong,  cross-reactive 
antibody responses to envelope proteins from divergent 
strains of SIV (Anderson et al., 2005). Moreover, rhesus 
macaques  immunized  with  SIV  HECs  and  challenged 
intravenously  with  SIVmac251,  made  neutralizing 
antibodies  targeting  the  challenge  strain  of  virus 
(Anderson et al., 2005). Our previous studies combined 
suggest  that  HIV  HECs  are  strongly  immunogenic, 
eliciting  both  cellular  and  humoral  immune  responses 
specific to the HIV  gp120. These studies also suggest 
that  our  HIV  HECs  are  able  to  induce  broadly 
neutralizing  antibodies.  Recently,  we  also  reported  an 
immunological comparison between lipidated and non-
lipidated multivalent HIV-1 peptides representing gp120 
and gag hypervariable regions (Ghunaim et al., 2011). 
  Although  we  followed  up  the  HIV  HEC-specific 
antibody response up to (Carlos et al., 2000), we did not 
determine  whether  memory  responses  elicited  by  HIV 
HECs could be detected several years after immunization. 
In the present study, performed more than 8 years after 
two  immunizations  were  administered  in  a  two-month 
interval, both macaques received a booster immunization 
to  measure  memory  immune  responses  specific  to  HIV 
HECs. This was done to specifically determine whether 
HIV  HECs  could  induce  the  long-lasting  anamnestic 
immune response required after effective vaccination. Our 
results showed that macaques immunized  with the HIV 
HEC peptide mixture retained strong antibody-producing 
B cell memory and lymphoproliferative responses specific 
to HIV HECs. In addition, this memory antibody response 
could  still  recognize  antigenic  epitopes  of  gp120  from 
diverse strains of HIV-1.  
  Overall,  these  results  suggest  that  our  multivalent 
peptide mixtures (HIV HECs), are strong immunogens, 
eliciting  both  humoral  and  cellular  immunity  that  is 
broadly reactive to epitopes found in divergent strains of 
HIV-1. In addition, HIV HECs are able to elicit not only 
early effector immune responses, but also strong, long-
lasting  memory  anamnestic  immune  responses  without 
causing  adverse  effects  in  non-human  primates.  These 
findings  could  contribute  to  the  design  of  a  vaccine 
against HIV and AIDS. We believe that these results are 
relevant to the likely possibility that individuals will be 
exposed  to  pathogenic  HIV-1  several  years  following 
vaccination. In this case, the initial infection would boost 
the  immune  response  triggering  the  memory  B  and  T 
cells to reduce the initial viremia and seeding of mucosal 
lymphoid organs with HIV-1. This effect could result in 
an  immune  response  that  delays  the  development  of 
AIDS by keeping the virus burden at a very low level in 
the lymphoid organs.  
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